Status:
TERMINATED
Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma
Lead Sponsor:
Intergroupe Francophone du Myelome
Conditions:
Multiple Myeloma
Covid19
Eligibility:
All Genders
18-110 years
Phase:
NA
Brief Summary
Among all MM patients included in the cohort at the time of diagnosis of SARS-CoV-2 infection, blood samples will be collected at inclusion, at time of the infection acute phase in the most severe cas...
Detailed Description
MM is a hematological malignancy, supposed mainly not curable, except for some exceptional patients, despite the availability of numerous new drugs. The patients are highly susceptible to infections, ...
Eligibility Criteria
Inclusion
- Patients with a multiple myeloma and a documented COVID19 (by RT-PCR, thoracic TDM, and/or antigenix test).
- Patients having received the information to participate in the research and having expressed their non-opposition
- Patients with social security insurance or equivalent
Exclusion
- Patients without multiple myeloma
- Patients without COVID19
- Patients under juridical protection guardianship, or tutelage measure
Key Trial Info
Start Date :
December 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
139 Patients enrolled
Trial Details
Trial ID
NCT04805203
Start Date
December 16 2020
End Date
December 31 2022
Last Update
October 19 2023
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens SUD
Amiens, France
2
CHRU Hôpital du Bocage
Angers, France
3
Ch Annecy Genevois
Annecy, France
4
CH Victor Dupouy
Argenteuil, France